(1S,3aS,3bS,9aR,9bS,11aS)-5,6,9a,11a-tetramethyl-7-oxo-N-phenyl-2,3,3a,3b,4,8,9,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (1S,3aS,3bS,9aR,9bS,11aS)-5,6,9a,11a-tetramethyl-7-oxo-N-phenyl-2,3,3a,3b,4,8,9,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
• 化学式: C₂₇H₃₆N₂O₂
• 分子量: 420.6
• InChiKey: AGSXLKPSTFWBMW-UEQBCOQUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• 4-azasteroid derivatives as androgen receptor modulators
  申请人：Wang Jiabing

  公开号：US20050131005A1

  公开（公告）日：2005-06-16

  Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式I的化合物以组织选择性的方式调节雄激素受体（AR）。它们在男性患者的前列腺或女性患者的子宫中作为雄激素受体拮抗剂，而在骨骼和/或肌肉组织中作为雄激素受体激动剂，因此可用于治疗由雄激素缺乏引起或可以通过雄激素管理改善的疾病，包括骨质疏松症、骨质疏松、糖皮质激素诱导的骨质疏松症、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、衰弱、老化皮肤、男性性腺功能减退症、女性更年期症状、动脉粥样硬化、高胆固醇血症、高脂血症、肥胖症、再生障碍性贫血和其他造血系统疾病、炎症性关节炎和关节修复、HIV消耗症、前列腺癌、癌性消瘦、阿尔茨海默病、肌肉萎缩症、早发性卵巢衰竭和自身免疫性疾病，可单独使用或与其他活性剂联合使用。
• 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP1501512A2

  公开（公告）日：2005-02-02
• US7625919B2
  申请人：——

  公开号：US7625919B2

  公开（公告）日：2009-12-01
• [EN] 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS<br/>[FR] DERIVES DE 4-AZASTEROIDE UTILISES COMME MODULATEURS DU RECEPTEUR DE L'ANDROGENE
  申请人：MERCK & CO INC

  公开号：WO2003092588A2

  公开（公告）日：2003-11-13

  Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compounds are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer s disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.